Pull to refresh
Logo
Roche bets $15 billion on Chinese antibody-drug conjugates

Roche bets $15 billion on Chinese antibody-drug conjugates

Money Moves

Hansoh deal is Roche's sixth China pact since late August as it rebuilds its cancer pipeline

Yesterday: Roche and Hansoh announce $15 billion ADC pact

Overview

Updated 1 hour ago

Roche will pay Hansoh Pharmaceutical up to $15 billion for a portfolio of antibody-drug conjugates, cancer drugs that carry a toxin directly to tumor cells. The Swiss drugmaker put $400 million down Monday, with $110 million more due in a year.

The pact is Roche's sixth licensing deal with a Chinese drugmaker since late August, and its second with Hansoh. Chinese firms now account for about 70% of global ADC development, per a December Goldman Sachs report. Roche's existing ADCs, Kadcyla and Polivy, together sold roughly $2.1 billion in the first half of 2026.

Why it matters

Roche is funneling billions into Chinese antibody-drug conjugate technology to keep its cancer revenue from eroding as the market shifts to next-generation therapies.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$15B
Maximum milestone value of the deal
Payments tied to development, regulatory approval, and commercialization, plus tiered royalties.
$510M
Guaranteed first-year payments
$400 million upfront plus $110 million due on the deal's first anniversary.
6
Roche China deals since late August
The Hansoh pact is the sixth, a faster pace than any pharmaceutical peer this year, per BioPharma Dive.
~70%
Share of global ADC development by Chinese firms
Figure from a December 2025 Goldman Sachs report cited in deal coverage.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

October 2025 October 2026

5 events Latest: Yesterday
Tap a bar to jump to that date
  1. Roche and Hansoh announce $15 billion ADC pact

    Latest Deal

    $400 million upfront, $110 million anniversary payment, up to $15 billion in milestones for a broad ADC portfolio.

  2. Roche partners with DualityBio on ADCs

    Deal

    Agreement for next-generation antibody-drug conjugates for patients who progressed after treatment.

  3. Roche's China deal surge begins

    Trend

    Run of Chinese licensing pacts begins, reaching six deals by mid-October.

  4. Roche signs ADC deal with MediLink

    Deal

    Licensing agreement covers an antibody-drug conjugate targeting several solid tumor types.

  5. Roche licenses first Hansoh ADC

    Deal

    Roche pays $80 million upfront, up to $1.45 billion in milestones, for ex-China rights to HS-20110.

Scenarios

1

Roche's ADC gamble lands a late-stage drug

Possible Resolves by Oct 19, 2028

Discussed by: BioPharma Dive and Fierce Biotech deal coverage

If the preclinical candidates produce solid data, several will move through Phase Ia under Hansoh, then into Roche's global development operation. The first visible signs would be trial registrations and early clinical readouts over the next two years.

2

Early failures shrink the $15 billion payday

Possible Resolves by Oct 19, 2028

Discussed by: Clinical trial base rates cited across oncology reporting

Most preclinical antibody-drug conjugates fail in early testing. If the lead programs stall, Hansoh keeps the guaranteed first-year payments but collects few of the milestone payments, which only arrive on development and approval benchmarks.

3

Roche and Hansoh expand to a third alliance

Possible Resolves by Oct 19, 2028

Discussed by: Fierce Biotech, noting the deal builds on the earlier HS-20110 pact

The current pact grew directly out of the first Hansoh collaboration. If early data look strong, the two companies could broaden the relationship further, matching the pattern of repeated, expanding deals.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

March 2019

AstraZeneca licenses Enhertu from Daiichi Sankyo (2019)

AstraZeneca paid $1.35 billion upfront plus milestone payments for rights to Enhertu, an antibody-drug conjugate, in markets outside Japan. The drug was later approved for several cancers and became one of the world's top-selling oncology treatments.

Then

Enhertu generated billions in annual sales and became a cornerstone of AstraZeneca's oncology line.

Now

The deal set the template for big upfront-plus-milestone ADC licensing arrangements across the industry.

Why this matters now

The structure of Roche's Hansoh deal—large upfront payment, milestone-loaded—mirrors the Enhertu model, the industry's proof that licensed ADCs can become blockbusters.

December 2023

Pfizer acquires Seagen (2023)

Pfizer agreed to buy Seagen for $43 billion, one of the largest biotech acquisitions ever, to gain its antibody-drug conjugate pipeline anchored by the blood cancer drug Adcetris.

Then

The deal closed in December 2023, giving Pfizer one of the largest ADC pipelines in the industry.

Now

It helped trigger a wave of ADC acquisitions and licensing as drugmakers paid premiums for the technology.

Why this matters now

Shows how far drugmakers will go for ADC capability and explains why Roche is committing billions rather than building the technology internally.

Sources

(5)